Skip to main content
Journal cover image

The emerging role of anti-angiogenic therapy for malignant glioma.

Publication ,  Journal Article
Reardon, DA; Desjardins, A; Rich, JN; Vredenburgh, JJ
Published in: Curr Treat Options Oncol
February 2008

Adults with glioblastoma multiforme (GBM), the most common primary brain tumor, have an unacceptably poor outcome with conventional cytotoxic therapies. Malignant gliomas are remarkably angiogenic, and vascular endothelial growth factor (VEGF) is the dominant pro-angiogenic factor. Recent clinical trials targeting VEGF signaling have achieved unprecedented rates of durable radiographic and clinical response, while also confirming adequate safety among recurrent malignant glioma patients. An array of additional clinical trials evaluating anti-angiogenic strategies are underway for both recurrent and newly diagnosed malignant glioma patients. Promising results of these approaches suggest that the treatment of GBM may represent an emerging paradigm of anti-angiogenic therapy.

Duke Scholars

Published In

Curr Treat Options Oncol

DOI

EISSN

1534-6277

Publication Date

February 2008

Volume

9

Issue

1

Start / End Page

1 / 22

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Oncology & Carcinogenesis
  • Humans
  • Glioma
  • Clinical Trials as Topic
  • Brain Neoplasms
  • Angiogenesis Inhibitors
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reardon, D. A., Desjardins, A., Rich, J. N., & Vredenburgh, J. J. (2008). The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol, 9(1), 1–22. https://doi.org/10.1007/s11864-008-0052-6
Reardon, David A., Annick Desjardins, Jeremy N. Rich, and James J. Vredenburgh. “The emerging role of anti-angiogenic therapy for malignant glioma.Curr Treat Options Oncol 9, no. 1 (February 2008): 1–22. https://doi.org/10.1007/s11864-008-0052-6.
Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ. The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol. 2008 Feb;9(1):1–22.
Reardon, David A., et al. “The emerging role of anti-angiogenic therapy for malignant glioma.Curr Treat Options Oncol, vol. 9, no. 1, Feb. 2008, pp. 1–22. Pubmed, doi:10.1007/s11864-008-0052-6.
Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ. The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol. 2008 Feb;9(1):1–22.
Journal cover image

Published In

Curr Treat Options Oncol

DOI

EISSN

1534-6277

Publication Date

February 2008

Volume

9

Issue

1

Start / End Page

1 / 22

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Oncology & Carcinogenesis
  • Humans
  • Glioma
  • Clinical Trials as Topic
  • Brain Neoplasms
  • Angiogenesis Inhibitors
  • 3211 Oncology and carcinogenesis